Leonard Schleifer - Regeneron Pharmaceuticals President CEO, Director

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:4em;padding-top: 25px;;'>RE</div>
REGN -- USA Stock  

Fiscal Quarter End: March 31, 2020  

Dr. Leonard S. Schleifer, M.D., Ph.D., is an President, Chief Executive Officer, Director of the Company. Dr. Schleifer founded the Company in 1988, was a Director and its President and Chief Executive Officer since its inception, and served as Chairman of the Board from 1990 through 1994. Dr. Schleifer, together with Regenerons founding scientist, Dr. Yancopoulos, built and has managed the Company over the past nearly 30 years
Age: 65  CEO Since 1994  Ph.D    
914 847-7000  www.regeneron.com
Schleifer is a licensed physician and is certified in Neurology by the American Board of Psychiatry and Neurology. With nearly 30 years of experience as Chief Executive Officer of the Company, Dr. Schleifer brings to the board an incomparable knowledge of the Company, significant leadership experience, and an indepth understanding of the complex research, drug development, and business issues facing companies in the biopharmaceutical industry.

Leonard Schleifer Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 13.61 % which means that it generated profit of $13.61 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 18.87 % meaning that it created $18.87 on every $100 dollars invested by stockholders.
The company currently holds 738 M in liabilities with Debt to Equity (D/E) ratio of 7.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Regeneron Pharmaceuticals has Current Ratio of 3.95 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 7 records

CEO Since

Murray KesslerPerrigo Company Plc
Kristin PeckZoetis
M RamanaDr Reddys Laboratories Ltd
Juan AlaixZoetis
MARC KIKUCHIDr Reddys Laboratories Ltd
Uwe RohrhoffPerrigo Company Plc
William NieburOrigin Agritech Limited

Company Summary

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 8100 people.Regeneron Pharmaceuticals (REGN) is traded on BATS Exchange in USA and employs 8,100 people.

Regeneron Pharmaceuticals Leadership Team

Charles Baker, Independent DirectorView
Joseph Goldstein, Independent DirectorView
Anthony Coles, Independent DirectorView
George Sing, Independent DirectorView
Peter Powchik, Senior Vice President - Clinical DevelopmentView
Jay Markowitz, Senior Vice President - Portfolio ManagementView
Robert Terifay, Sr. VP of CommercialView
Robert Landry, CFO and Sr. VP of Fin.View
Michael Brown, Independent DirectorView
Christine Poon, Independent DirectorView
Neil Stahl, Executive VP of RandDView
Marion McCourt, Senior Vice President and Head of CommercialView
George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, DirectorView
Huda Zoghbi, DirectorView
Bonnie Bassler, DirectorView
Joseph LaRosa, Senior Vice President General Counsel, SecretaryView
Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product SupplyView
Leonard Schleifer, President CEO, DirectorView
Alfred Gilman, Independent DirectorView
Roy Vagelos, Chairman of the BoardView
Michael Aberman, Vice President - StrategyView
Manisha Narasimhan, IR ContactView
Douglas McCorkle, Vice President Controller, Assistant TreasurerView
Marc TessierLavigne, Independent DirectorView
Christopher Fenimore, Vice President ControllerView
Arthur Ryan, Independent DirectorView

Stock Performance Indicators

Return On Equity18.87
Return On Asset13.61
Profit Margin29.03
Operating Margin32.16
Current Valuation38.97 B
Shares Outstanding107.98 M
Shares Owned by Insiders24.60
Shares Owned by Institutions71.16
Number of Shares Shorted2.89 M
Price to Earning19.75